These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12756833)

  • 1. [Attitude of patient associations to clinical trials of new drugs].
    Tybkjaer HW; Witte L; Johannessen MB
    Ugeskr Laeger; 2003 Apr; 165(16):1688-90. PubMed ID: 12756833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of the Danish Medical Products Agency in clinical trials].
    Simonsen AC
    Ugeskr Laeger; 2003 Apr; 165(16):1653-6. PubMed ID: 12756821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The inspection by the Danish Medical Products Agency of drug clinical trials].
    Jacobsen E; Stilbo I
    Ugeskr Laeger; 2003 Apr; 165(16):1656-8. PubMed ID: 12756822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [How to establish GCP-units in Denmark?].
    Krogsgaard K; Andreasen PB
    Ugeskr Laeger; 2003 Apr; 165(16):1665-7. PubMed ID: 12756825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Communication and information in the Danish health services. Laws, regulations and rules for patients and personnel in the Danish health services].
    Baek-Jensen J; Mainz J; Bitsch O; Keller JØ; Hougaard K
    Ugeskr Laeger; 2001 Dec; 164(1):29-33. PubMed ID: 11810793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are better endpoints and better design of clinical trials needed?
    Fransen J; van Riel PL
    Best Pract Res Clin Rheumatol; 2004 Feb; 18(1):97-109. PubMed ID: 15123040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The GCP directive--consequences for clinical drug research].
    Gluud CN
    Ugeskr Laeger; 2003 Apr; 165(16):1662-4. PubMed ID: 12756824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard?
    Boers M
    Arthritis Rheum; 2003 Jun; 48(6):1481-3. PubMed ID: 12794813
    [No Abstract]   [Full Text] [Related]  

  • 9. How some patients in new-drug trials can get cut off.
    Anand G
    Wall St J (East Ed); 2003 Dec; ():A1, A11. PubMed ID: 14971381
    [No Abstract]   [Full Text] [Related]  

  • 10. Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies.
    Woodworth TG; Furst DE; Strand V; Kempeni J; Fenner H; Lau CS; Miller F; Day R; Lipani J; Brooks P
    J Rheumatol; 2001 May; 28(5):1163-9. PubMed ID: 11361207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How and when to use DMARDs.
    Simmons S
    Nurse Pract; 2010 Aug; 35(8):12-4. PubMed ID: 20644444
    [No Abstract]   [Full Text] [Related]  

  • 12. SOP 05: Patient information and informed consent.
    Onkologie; 2003 Oct; 26 Suppl 6():23-33. PubMed ID: 23570181
    [No Abstract]   [Full Text] [Related]  

  • 13. [Patient rights in training situations].
    Landex NL; Hartlev M
    Ugeskr Laeger; 2010 Feb; 172(8):620-2. PubMed ID: 20184818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primer: establishing a clinical trial unit - regulations and infrastructure.
    Fleischmann R
    Nat Clin Pract Rheumatol; 2007 Apr; 3(4):234-9. PubMed ID: 17396109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From a constitutional right to a policy of exceptions: Abigail Alliance and the future of access to experimental therapy.
    Shah S; Zettler P
    Yale J Health Policy Law Ethics; 2010; 10(1):135-96. PubMed ID: 20229846
    [No Abstract]   [Full Text] [Related]  

  • 16. Who should go first in trials with scarce agents? The views of potential participants.
    Pentz RD; Flamm AL; Sugarman J; Cohen MZ; Xu Z; Herbst RS; Abbruzzese JL
    IRB; 2007; 29(4):1-6. PubMed ID: 17847620
    [No Abstract]   [Full Text] [Related]  

  • 17. The new British Society for Rheumatology disease modifying anti-rheumatic drugs guidelines.
    Deighton C; Gadsby K
    Musculoskeletal Care; 2006 Sep; 4(3):174-81. PubMed ID: 17042028
    [No Abstract]   [Full Text] [Related]  

  • 18. Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index.
    Welch V; Singh G; Strand V; Fries J; Boers M; Ramey D; Day RO; Brooks P; Tugwell P; Clinch J; Kristjansson B
    J Rheumatol; 2001 May; 28(5):1188-91. PubMed ID: 11361211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients' attitudes towards, and information needs in relation to, nurse prescribing in rheumatology.
    Berry D; Bradlow A; Courtenay M
    J Clin Nurs; 2008 Jan; 17(2):266-73. PubMed ID: 18171396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The personal data act, clinical trials and data privacy. Rules for treatment of personal data in clinical trials and scientific research projects].
    Daasnes C
    Ugeskr Laeger; 2003 Apr; 165(16):1683-5. PubMed ID: 12756831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.